Group 1 - The company has decided to use idle self-owned funds not exceeding 2 billion RMB for cash management, effective for 12 months from the approval date by the shareholders' meeting [1] - Recently, the company has utilized 300 million RMB of idle funds to purchase certain financial products, with no related party relationships with the signing institutions [2] - The company aims to enhance the value of idle funds and improve cash operation returns while ensuring the operational funding needs and safety of the company and its subsidiaries [5] Group 2 - The company will select low-risk investment products with high safety and liquidity for cash management, but acknowledges potential risks due to market fluctuations and liquidity constraints [3] - To mitigate risks, the company has established an internal management mechanism, maintains reasonable cash reserves, and implements a diversified investment strategy [4] - The company has set up an effective internal control system, with the audit department supervising cash management activities and reporting to the board of directors and the audit committee [4]

Core Viewpoint - The U.S. Food and Drug Administration (FDA) has declined to approve Disc Medicine's experimental drug bitopertin for treating erythropoietic protoporphyria, leading to a significant drop in the company's stock price by 31.6% to $48.90 [1]. Company Summary - Disc Medicine was seeking FDA approval for bitopertin, aimed at treating a rare genetic metabolic disorder caused by a deficiency of the ferrochelatase enzyme [1]. - The primary symptom of erythropoietic protoporphyria is hypersensitivity of the skin to sunlight [1].

Legal Developments - Johnson & Johnson (JNJ) was found liable by a Pennsylvania jury for the ovarian cancer of a woman who used its talc-based baby powder, resulting in a damages award of $250,000, which includes $50,000 in compensatory damages and $200,000 in punitive damages [2][11] - The company maintains that its talc products are safe and do not contain asbestos, although it has transitioned to a cornstarch-based formula globally [3] Energy Sector Advancements - Amazon (AMZN)-backed nuclear startup X-energy, through its subsidiary TRISO-X, received U.S. regulatory approval for its advanced reactor fuel, marking a significant step for the deployment of small modular reactors (SMRs) [4][11] - This approval is part of a broader "nuclear renaissance" aimed at providing carbon-free, 24/7 power for artificial intelligence workloads, with the U.S. Department of Energy accelerating these approvals to enhance domestic energy security [5] Corporate Finance Trends - UBS forecasts a significant increase in corporate buybacks, predicting activity to rise from recent lows to between $30 billion and $50 billion per week over the next six weeks, which could provide a boost to equity markets [6][7][11] Oil Market Insights - Crude oil futures experienced modest gains, with Brent Crude settling at $67.75 per barrel and U.S. West Texas Intermediate (WTI) crude at $62.89 per barrel [8][11] - This increase occurred despite a bearish report from the International Energy Agency (IEA) that lowered its global demand forecast for 2026, with the market remaining cautious about a projected surplus of 3.7 million barrels per day [9]

Core Viewpoint - A class action lawsuit has been filed against Inovio Pharmaceuticals for alleged violations of securities laws due to misleading statements regarding its manufacturing capabilities and regulatory submissions [1][4]. Group 1: Lawsuit Details - The Schall Law Firm is representing investors in a class action lawsuit against Inovio Pharmaceuticals for violations of the Securities Exchange Act of 1934 [1]. - Investors who purchased Inovio's securities between October 10, 2023, and December 26, 2025, are encouraged to participate in the lawsuit before the deadline of April 7, 2026 [2]. - The lawsuit claims that Inovio made false and misleading statements about its CELLECTRA device and the likelihood of filing the INO-3107 Biologics License Application (BLA) by the second half of 2024 [4]. Group 2: Allegations Against Inovio - The complaint alleges that Inovio suffered from manufacturing deficiencies and failed to provide sufficient evidence for an FDA priority review or accelerated approval for its BLA [4]. - As a result of these misleading statements, investors experienced damages when the truth about Inovio's situation was revealed [4].

DANI: HAPPY FRIDAY THE 13TH, CPI DATA. 30 MINUTES UNTIL THE START OF THE CASH EQUITY TRADE. MATT MILLER IS ON A WELL DESERVED VACATION. OPEN INTEREST STARTS NOW. DANI: COMING UP, AN INFLATION REPORT CAP IS A BUSY WEEK OF ECONOMIC DATA. CORE CPI RISING IN JANUARY ON HIGHER SERVICING COSTS. THE AI SCARE TRADE CAME FOR A WIDE RANGE OF STOCKS, EVERYTHING LOGISTICS. THAT IS THE LATEST VICTIM. ANOTHER WAVE OF EARNINGS FROM EV'S TO PHARMA AND FOOD. THE LATEST READ ON CORPORATE AMERICA. ONE OF THOSE READS, RIVIAN D ...

Core Viewpoint - Sanofi has announced a leadership change, appointing Belén Garijo as the new CEO effective April 29, 2026, following the decision not to renew the mandate of current CEO Paul Hudson, which has led to a 4.5% drop in shares on February 12, 2026 [1][7]. Leadership Change - Paul Hudson's last day as CEO will be February 17, 2026, and Olivier Charmeil will serve as interim CEO until Garijo takes over [2]. - Belén Garijo, a Spanish national, previously served as CEO of Merck KGaA and has held roles at Abbott Laboratories and Sanofi [2]. Market Reaction - Investors have reacted negatively to the sudden CEO change, expressing concerns over Garijo's lack of a proven track record in leading large companies [3]. Stock Performance - Over the past six months, Sanofi's shares have declined by 4.1%, contrasting with a 28.4% increase in the industry [4]. Company Challenges - Sanofi is recognized as a major vaccine manufacturer and has a significant immunology drug, Dupixent, expected to generate around €22 billion in sales by 2030 [5]. - The company has faced setbacks in its research and development (R&D) efforts and pipeline innovation, which may have contributed to the decision for a leadership change [8][9]. - Sanofi has lagged in mergers and acquisitions compared to peers, impacting its growth and diversification [9]. Future Focus - Garijo's primary objectives will include enhancing R&D productivity, governance, and innovation, with the potential to turn around the company's fortunes [10].

Core Viewpoint - The presentation highlights the participation of AbbVie in Piper's Virtual Immunology Symposium, emphasizing the importance of data readouts as the year progresses [1][2]. Group 1 - AbbVie is represented by Chief Scientific Officer Roopal Thakkar and Vice President of Immunology Development Kori Wallace at the symposium [1]. - The symposium is focused on immunology, indicating a significant interest in this area within the industry [1].

Core Insights - MetaVia Inc. has announced a strong global intellectual property portfolio for its lead asset, DA-1726, which is aimed at treating obesity and related metabolic disorders, securing 39 granted and pending patents that extend protection until 2041 [1][2] Company Performance - The company's CEO highlighted the significance of the intellectual property, emphasizing the unique design of DA-1726 as a dual GLP-1/glucagon agonist, with recent clinical data showing a 9% weight loss at the 48 mg dose and improvements in waist size and blood sugar levels [2] - MetaVia's stock is currently trading 21.8% below its 20-day simple moving average and 77.6% below its 200-day SMA, indicating significant bearish pressure, with shares down 90.85% over the past 12 months [3] - The stock's RSI is at 23.34, suggesting it may be undervalued and could rebound, while the MACD indicates potential bullish momentum despite the overall bearish trend [4] Sector Comparison - MetaVia is outperforming its sector with a gain of approximately 10.2%, while the Healthcare sector has only increased by 0.17%, reflecting a significant deviation from recent sector trends [5] - The Healthcare sector has seen a slight decline of 1.18% over the past 30 days but has gained 2.83% over the last 90 days, indicating mid-tier performance in the market [5] Analyst Consensus - The stock carries a Buy Rating, with recent analyst actions including HC Wainwright & Co. raising the target price to $40.00 [6] - At the time of publication, MetaVia shares were up 9.64% at $1.84, trading near its 52-week low of $1.61, with key resistance at $2.00 and support at $1.50 [6]

Core Viewpoint - A class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. for alleged securities fraud, impacting investors who purchased shares between October 10, 2023, and December 26, 2025 [1]. Group 1: Lawsuit Details - The lawsuit claims that Inovio made materially false and misleading statements regarding its business operations and prospects during the class period [1]. - Investors have until April 7, 2026, to file a lead plaintiff motion in the ongoing lawsuit [1]. - The complaint alleges that Inovio failed to disclose significant issues related to its CELLECTRA device manufacturing and the likelihood of timely FDA submission for its INO-3107 treatment [1]. Group 2: Stock Price Impact - Following the announcement of a delay in the BLA submission for INO-3107 due to manufacturing issues, Inovio's stock price fell by $0.27, or 3.1%, closing at $8.44 on August 9, 2024 [1]. - On December 29, 2025, after the FDA accepted the INO-3107 BLA on a standard review timeline, the stock price dropped by $0.56, or 24.45%, closing at $1.73 [1]. Group 3: Allegations of Misleading Information - The lawsuit alleges that Inovio overstated the regulatory and commercial prospects of INO-3107, leading to materially misleading statements about the company's business [1]. - Specific allegations include deficiencies in manufacturing for the CELLECTRA device and insufficient information to justify eligibility for FDA accelerated approval [1].

Core Viewpoint - A class action lawsuit has been filed against Kyndryl Holdings, Inc. for securities fraud, following significant management departures and issues with financial reporting, leading to a substantial drop in stock price [1]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of shareholders who acquired Kyndryl securities between August 7, 2024, and February 9, 2026, with a deadline for filing a lead plaintiff motion set for April 13, 2026 [1]. - The lawsuit alleges that Kyndryl made materially false and misleading statements regarding its business operations and financial health during the class period [1]. - Specific allegations include that Kyndryl's financial statements were materially misstated, lacked adequate internal controls, and that the company would be unable to timely file its quarterly report [1]. Group 2: Company Developments - On February 9, 2026, Kyndryl announced the immediate departure of its CFO and General Counsel, which raised concerns about its internal controls and financial reporting practices [1]. - The company indicated it anticipates reporting material weaknesses in its internal control over financial reporting, particularly regarding communication and management practices [1]. - Following these announcements, Kyndryl's stock price fell by $12.90, or 54.9%, closing at $10.59 per share on the same day [1].